Health news
The Food and Drug Administration (FDA) has expanded the approval of Veklury® (remdesivir; Gilead Sciences) to include treatment of COVID-19 in nonhospitalized patients aged 12 years and older (weighing at least 40kg) with mild to…
The safety and efficacy of a shorter 5-day course of antibiotics were found to be comparable to a standard 10-day course in children with uncomplicated community-acquired pneumonia (CAP), according to the findings of a clinical…
Influenza vaccination reduces the risk of serious illness in children even when the circulating virus is antigenically different from the vaccine virus, according to a Centers for Disease Control and Prevention (CDC) study published in…
Off-label use of cardiovascular (CV) drugs in home therapy is common for children with congenital or acquired heart disease, according to a study published in The American Journal of Cardiology. Researchers reviewed the records of…
A large systematic review of the effects of asthma on the risk of poor COVID-19 outcomes in adults and children found that, overall, asthma was not associated with severe COVID-19 outcomes, although the evidence supporting…
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommends the use of a single booster dose of the Pfizer-BioNTech COVID-19 vaccine in individuals 12 to 15 years of age…
Children with simple febrile seizures (SFS) can be managed without lumbar puncture (LP) testing, according to findings published in Pediatrics. With Haemophilus influenzae and conjugated pneumococcal vaccines, the prevalence of bacterial meningitis has decreased dramatically…
Among children, pet-keeping has been shown to increase the risk for respiratory symptoms, particularly asthma and asthma-associated symptoms. A cross-sectional study was conducted to examine the link between domestic pets and respiratory health among schoolchildren…
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents 13 years of age and older. Previously, the treatment was only approved…
The Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older and active juvenile psoriatic arthritis (JPsA) in patients 2…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021